Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding.
Patrick Wettstein, André Haeberli, Monika Stutz...
https://pubmed.ncbi.nlm.nih.gov/15502066/Actively Recruiting
Led by Christian Haslinger · Updated on 2026-04-27
988
Participants Needed
9
Research Sites
26 weeks
Total Duration
This research focuses on postpartum hemorrhage PPH, a major cause of maternal illness and death worldwide, defined as blood loss of 500 mL or more within 24 hours after delivery. The study aims to determine if early replenishment of coagulation factor XIII FXIII can reduce postpartum blood loss and related complications. Current treatments mainly focus on fibrinogen replacement, but evidence for its effectiveness is inconclusive, prompting investigation of FXIIIs role based on previous studies showing its association with blood loss. Women who experience PPH with measured blood loss of at least 500 mL receive 1g of tranexamic acid intravenously as standard care. If bleeding continues and exceeds 700 mL, participants are randomly assigned to one of two groups the intervention group receives FXIII Fibrogammin intravenously at doses based on weight in addition to standard care, while the control group receives standard care alone. This is a nationwide, multi-center, open-label, randomized controlled trial conducted in perinatal centers across Switzerland. Participants will be monitored for blood loss during the first 24 hours after delivery as the primary outcome. Additional assessments include clinical outcomes of PPH at around 48 hours postpartum, changes in blood tests such as hemoglobin and platelet counts before delivery and at 48 hours, hospital costs, breastfeeding status at 6 to 9 weeks, and patient surveys shortly after hospital discharge. The study includes safety monitoring and follow-up during hospital stay and beyond, with participation lasting up to nine weeks after delivery.
CONDITIONS
SWIFT - SWIss Factor XIII Trial in PPH
C
Christian Haslinger, Prof. Dr
A
Annick Toggenburger, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Christian Haslinger
Lead Sponsor
Swiss National Science Foundation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 hours after delivery
Participants receive standard care for postpartum hemorrhage. Those in the intervention group receive FXIII (Fibrogammin) intravenously when blood loss exceeds 700 mL to help reduce bleeding and PPH-related complications.
Treatment is administered as needed based on blood loss after delivery
Duration - Up to 9 weeks after delivery
Participants are monitored for outcomes related to postpartum hemorrhage, including blood counts and breastfeeding status, up to 9 weeks after delivery.
Approximately 3 to 5 days post-delivery visit, and additional visits up to 6 to 9 weeks postpartum
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Patrick Wettstein, André Haeberli, Monika Stutz...
https://pubmed.ncbi.nlm.nih.gov/15502066/GBD 2015 Maternal Mortality Collaborators
https://pubmed.ncbi.nlm.nih.gov/27733286/Christian Haslinger, Torsten Hothorn, Verena Bossung...
https://pubmed.ncbi.nlm.nih.gov/40345697/Lale Say, Doris Chou, Alison Gemmill...
https://pubmed.ncbi.nlm.nih.gov/25103301/Wolfgang C Korte, Christine Szadkowski, Anita Gähler...
https://pubmed.ncbi.nlm.nih.gov/19194150/A Weeks
https://pubmed.ncbi.nlm.nih.gov/25289730/Jeremy W Jacobs, Elizabeth A Abels, Brian D Adkins...
https://pubmed.ncbi.nlm.nih.gov/41472522/Christian Haslinger, Wolfgang Korte, Torsten Hothorn...
https://pubmed.ncbi.nlm.nih.gov/32176833/Christian Haslinger
Lead Sponsor
Swiss National Science Foundation
Collaborating Sponsor